New hope for Hard-to-Treat prostate cancer: enhertu trial launches

NCT ID NCT06610825

Recruiting now Disease control Sponsor: Washington D.C. Veterans Affairs Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests Enhertu, a targeted drug, in 60 men with HER2-positive prostate cancer that has spread and stopped responding to hormone therapy and newer drugs like abiraterone. Participants must have tried or refused chemotherapy. The study measures tumor shrinkage and how long the cancer is controlled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Enhertu (fam-trastuzumab deruxtecan-nxki)
What this could lead to: If it works, this could offer a new treatment option for men with HER2-positive prostate cancer that has stopped responding to hormone therapy and chemotherapy.
What could go wrong: This is a small, early-phase trial with only 60 people, so results may not apply to everyone. Enhertu can cause serious side effects like lung inflammation or heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRPC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRPC PROSTATE CANCER PROSTATE CANCER METASTATIC

Contacts and locations

Locations

Washington DC VAMC
RECRUITING

Washington D.C., District of Columbia, 20422, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.